October 4, 2022
Loading...
You are here:  Home  >  Banking & Finance  >  Tri-County Public Companies  >  Earnings  >  Current Article

Atara Biotherapeutics net losses worse than expected by analysts

IN THIS ARTICLE

Second quarter net losses for Atara Biotherapeutics outpaced analyst expectations, nearly doubling from the same period in 2017 to $50.9 million. Research and development costs rose 82.5 percent to $33.4 million, including new clinical trials, increased headcount and its recent expansion into a new R&D headquarters in Thousand Oaks. The company received positive results from…

Subscribe

    This article is only available to Business Times subscribers
  • Subscribers: or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.